BackPharmaBlock Sciences (Nanjing) Overview

PharmaBlock Sciences (Nanjing) EBIT

PharmaBlock Sciences (Nanjing)'s EBIT is $230M, below the sector sector average of $2.4T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$57.87M
↑ 11.68% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$232.69M
↓ 16.88% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

PharmaBlock Sciences (Nanjing) (300725.SZ) FAQ

The latest EBIT for 300725.SZ is $230M as of September 2026. That compares with $280M in the prior-year period — down 16.9% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside PharmaBlock Sciences (Nanjing)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 300725.SZ's EBIT moved from $280M to $230M — a 16.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in PharmaBlock Sciences (Nanjing)'s operating scale or balance-sheet position.

Against its sector companies, 300725.SZ currently prints $230M for EBIT, while the sector average sits near $2.4T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at PharmaBlock Sciences (Nanjing)'s growth, margins, and balance sheet.

A EBIT figure of $230M for 300725.SZ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.

After noting 300725.SZ's EBIT ($230M), review year-over-year change from $280M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.